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a  b  s  t  r  a  c  t
Obesity  is  a risk  factor  for various  cardiovascular  diseases  including  hypertension,  atherosclerosis,  and
myocardial  infarction.  Recent  studies  aimed  at understanding  the  microenvironment  of adipose  tissue
and its impact  on  systemic  metabolism  have  shed  light  on  the  pathogenesis  of obesity-linked  cardiovascu-






proteins  known  as adipokines.  Obesity  leads  to  increased  expression  of  pro-inﬂammatory  adipokines
and  diminished  expression  of  anti-inﬂammatory  adipokines,  resulting  in  the  development  of  a  chronic,
low-grade  inﬂammatory  state.  This  adipokine  imbalance  is  thought  to  be a key  event in  promoting  both
systemic  metabolic  dysfunction  and  cardiovascular  disease.  This  review  will  focus  on  the  adipose  tis-
sue  microenvironment  and  the  role of  adipokines  in  modulating  systemic  inﬂammatory  responses  that
contribute  to cardiovascular  disease.© 2013  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
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ntroduction
Obesity and associated metabolic disorders are becoming major
ealth care concerns around the world. It is estimated that over
0% of adults and 30% of children are overweight in the USA, and if
rends continue more than 50% of the world’s adult population will
e overweight in a few decades [1–3]. Obesity and its comorbidities
ave a devastating effect on vascular function and create conditions
production in the adipose tissue of pro- and anti-inﬂammatory
cytokines, referred to as adipokines, which contribute to the devel-
opment of metabolic and cardiovascular diseases.
Obesity-induced changes in adipose tissue
microenvironment
To understand how obesity has an impact on cardiovascular
hat favor cardiovascular disease. Obesity promotes cardiovascular
isease via many mechanisms including ectopic lipid deposition,
yperglycemia, and the development of a procoagulant state, to
ame a few. This review will focus on how obesity inﬂuences the
∗ Corresponding author at: Boston University Medical Campus, 715 Albany Street,
611, Boston, MA  02118, USA. Tel.: +1 617 414 2390; fax: +1 617 414 2391.
E-mail address: kxwalsh@bu.edu (K. Walsh).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.11.006function, it is important to ﬁrst focus on obesity-induced changes
in the microenvironment of adipose tissue (Fig. 1). The excess of
caloric intake leads to an expansion of the adipose tissue that
is initially driven by an increase in the number of adipocytes
(adipocyte hyperplasia) mediated by the recruitment and prolifer-
ation of adipogenic progenitors [4–7]. This hyperplastic response is
severely blunted with age [8], so the sustained exposure to exces-
sive energy intake ultimately leads to an increase in adipocyte size
(adipocyte hypertrophy) that compromises the functionality of the
vier Ltd. All rights reserved.
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Fig. 1. Obesity-linked changes in adipose tissue composition. Obesity can promote changes in adipose tissue and promote the transition to a metabolically dysfunctional
phenotype. As the body develops obesity, adipocytes undergo hypertrophy due to the increased storage of triglycerides. Macrophages in lean fat express markers of a M2
or  “alternatively activated” state, whereas obesity leads to recruitment and accumulation of a M1 or “classically activated” state with macrophages and CD8+ T cells in
adipose  tissue. Metabolically dysfunctional adipose tissue is indicated by the presence of crown-like histological structures that represent activated M1-like macrophages




































pf  pro-inﬂammatory factors are produced in obese states.
dipose tissue [6,9]. In advanced obesity, lipid-laden hypertrophied
dipocytes undergo necrotic and/or apoptotic cell death, contribut-
ng to the recruitment of inﬂammatory cells and to adipose tissue
ysfunction [10–12].
Whereas adipose tissue is mainly composed of adipocytes, other
ell types, including lymphocytes, macrophages, ﬁbroblasts, and
ascular cells, also appear to have important roles in controlling
he functional status of this tissue. Obesity leads to major changes
n the cellular composition of adipose tissue and also modulates the
henotype of individual cells within this tissue. For example, adi-
ose tissue from obese organisms is inﬁltrated by a large number
f macrophages, leading to increases in both absolute macrophage
umber and the relative level of macrophage-to-adipocyte ratio.
acrophage recruitment to adipose tissue is associated with sys-
emic inﬂammation and insulin resistance [13,14]. In addition
o this quantitative change, the macrophage phenotype is also
ltered by the obese state. The M1/M2  concept is a convenient
eans for classifying the inﬂammatory status of the macrophage.
acrophages that accumulate in adipose tissue of obese organisms
end to express genes associated with a M1-like or “classically acti-
ated” phenotype. In contrast, adipose tissue macrophages from
ean organisms tend to express genes associated with a M2-like
r “alternatively activated” phenotype [15]. Stimulation with T
elper 1 (TH1)-type cytokines, including interferon-, or bacterial
roducts will promote the M1-like phenotype in macrophages. M1
acrophages produce pro-inﬂammatory cytokines, such as tumor
ecrosis factor (TNF), express inducible nitric oxide synthase
iNOS), and produce high levels of reactive oxygen and nitrogen
ntermediates [16]. This class of macrophages is typically associ-
ted with inﬂammation and tissue destruction. On the other hand,
2-like macrophages preferentially express anti-inﬂammatory
ytokines, such as interleukin (IL)-10, and the enzyme arginase-
, which inhibits iNOS activity. These types of macrophages tend
o be associated with wound healing, angiogenesis, and the resolu-
ion of inﬂammation [16]. It is believed that M1-like macrophages
romote insulin resistance, whereas M2-like macrophages protectagainst obesity-induced insulin resistance [17]. Supporting this
notion, ablation of CD11c-positive, M1-like macrophages normal-
izes insulin sensitivity in obese mice [18].
Another distinctive feature of adipose tissue from obese orga-
nisms is the presence of “crown-like” structures in histological
sections. These features represent macrophages that surround dead
or dying adipocytes [10,11]. Obese subjects lacking crown-like
structures exhibit better metabolic control, diminished inﬂamma-
tory gene expression, and reduced cardiovascular risk than body
mass-matched individuals who display this histological feature
[19]. On the other hand, the number of crown-like structures in adi-
pose tissue is correlated with inﬂammation and insulin resistance
in metabolic syndrome patients [10,19]. Typically macrophages
function to rapidly remove dead cell debris prior to the disrup-
tion of their membranes. Thus, it is tempting to speculate that
the presence of crown-like structures signiﬁes a breakdown in the
phagocytic process in adipose tissue, thereby exacerbating the pro-
inﬂammatory state.
Obesity also inﬂuences the subsets of T cells that are present in
adipose tissue, where they appear to function in the regulation of
macrophage phenotype. CD4+ regulatory T cells and TH2-polarized
cells are found in higher abundance in the adipose tissue of lean
mice, and these cells contribute to the maintenance of adipose tis-
sue function and insulin sensitivity, in part through promoting an
anti-inﬂammatory alternative activation of macrophages [20,21].
On the other hand, under conditions of obesity, the accumulation
of CD8+ effector T cells and CD4+ TH1 cells in the adipose tissue
will generate TH1 signals and initiate the recruitment and activa-
tion of macrophages, perpetuating the pro-inﬂammatory cascade
that is associated with insulin resistance [21,22]. Thus, obesity-
induced alterations in the balance of TH1- and TH2-type signals
are likely to inﬂuence macrophage recruitment and phenotype in
adipose tissue, thereby generating either a pathogenic or a pro-
tective environment. B cells also appear to have a pivotal role
in obesity-induced adipose tissue inﬂammation, promoting T cell
and macrophage activation and contributing to insulin resistance
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23]. Similarly, mast cells have been reported to accumulate in
bese adipose tissue before the appearance of macrophages, and
tudies in mast-cell deﬁcient mice suggest a role for this cell-type
n obesity-associated metabolic dysfunction [24]. Neutrophil inﬁl-
ration and activation also contributes to adipose tissue dysfunction
hrough the action of neutrophil elastase [25,26]. Finally, it has
een reported that eosinophils in adipose tissue promote alterna-
ive activation of macrophages and glucose tolerance through the
roduction of the TH2 cytokine IL-4 [27]. Therefore, the status of
mmune cells in adipose tissue is an area of intense investigation,
nd a better understanding of the interplay between inﬂammation
nd metabolism is warranted.
Of particular relevance to the subject of this review, a num-
er of provocative studies have made the case that obesity is also
ssociated with changes in vascular structure and function within
dipose tissue. Several studies in patients and animal models have
hown that obesity causes capillary rarefaction in adipose tissue,
nd this leads to localized hypoxia [28–31]. In contrast with these
tudies, a recent report showed that obese human subjects display
ncreased rather than decreased oxygen tension in adipose tissue,
espite reduced adipose tissue blood ﬂow [32]. However, it must
e noted that, while suggesting an overall hyperoxic state, this lat-
er study does not rule out the possibility of localized hypoxic areas
ithin adipose tissue, and therefore further studies are required in
his ﬁeld. Regardless, the various studies coincide in their ﬁndings
f decreased adipose tissue capillarization, which may  limit nutri-
nt delivery and contribute to insulin resistance. Alternatively, this
ascular dysfunction could contribute to adipose tissue inﬂamma-
ion by promoting ischemia-induced adipocyte necrosis, followed
y macrophage recruitment and activation. Recent studies with
enetically engineered mice have provided conclusive evidence
f the role of adipose tissue vascularization in obesity-associated
etabolic dysfunction. Experiments with mice overexpressing vas-
ular endothelial growth factor A (VEGF-A) in adipocytes show that
ncreased VEGF-mediated angiogenesis in white adipose tissue can
ttenuate some of the metabolic effects of diet-induced obesity,
uch as insulin resistance and hepatic steatosis [33–35]. Conversely,
dipocyte-restricted deletion of VEGF-A results in scarce adipose
issue vascularization, which leads to increased adipose tissue
nﬂammation and systemic insulin resistance and glucose intol-
rance, as well as hepatic steatosis [35]. Furthermore, it has been
eported that hypoxia-inducible factor 1 (HIF1) – a master regu-
ator of VEGF expression – is upregulated during obesity-associated
dipose tissue expansion [36]. Interestingly, various experiments in
enetically engineered mice suggest that HIF1 does not inﬂuence
dipose tissue capillarization, but promotes adipose tissue expan-
ion, inﬂammation, and ﬁbrosis, leading to systemic metabolic
ysfunction [37–40].
The phenotypic changes in adipose tissue that result from obe-
ity are also thought to induce vascular endothelial cell activation.
ecause activated endothelial cells express adhesion molecules and
hemotactic factors that contribute to the recruitment of inﬂam-
atory cells, it is reasonable to speculate that obesity promotes
 vicious cycle of endothelial activation and tissue inﬂamma-
ion that contributes to adipose tissue dysfunction. Supporting
his notion, it has been shown that endothelial cells within the
dipose tissue of obese mice express higher levels of adhesion
olecules such as P-selectin, E-selectin, and intercellular adhesion
olecule 1 (ICAM-1). Moreover, administration of anti-ICAM-1
ntibody to obese mice prevents leukocyte-endothelium inter-
ctions and macrophage inﬁltration into adipose tissue [41]. In
ddition, adipose tissue inﬂammation may  also promote a state
f systemic endothelial cell activation through the endocrine
ctions of inﬂammatory adipokines such as TNF (see below),
hich could contribute to obesity-associated cardiovascular
isease.diology 63 (2014) 250–259
The adipokine concept
Accumulating evidence from animal models indicates that the
pathogenesis of obesity-related metabolic dysfunction involves
the development of a systemic, low-grade inﬂammatory state
[42,43]. Epidemiological studies have also demonstrated a connec-
tion between metabolic disease and a low-grade inﬂammation. For
example, increasing adipose mass in obese women is associated
with increased serum levels of the pro-inﬂammatory marker C-
reactive protein (CRP) [44]. Furthermore, high levels of CRP and
IL-6, are predictive of the development of type 2 diabetes [44,45]. In
contrast, weight loss leads to reductions in circulating levels of CRP
and IL-6 [46]. These ﬁndings strongly suggest that obesity is highly
associated with chronic low-grade inﬂammation, and it is believed
that this obesity-linked inﬂammatory state is due to changes in
the expression of cytokines by adipose tissue. Over the past two
decades, it has become apparent that adipose tissue is a source of
secreted immunomodulatory proteins, and that these adipokines
act as modulators of metabolic and cardiovascular processes.
While adipose tissue is mainly found in visceral and subcuta-
neous depots, it is also widely dispersed throughout the body. Other
depot sites that may  be particularly relevant in inﬂuencing cardio-
vascular disease include epicardial, perivascular, and pulmonary
adipose tissue. Whilst adipose tissue depots differ from one another
based upon their relative levels of adipokine production, obesity
will generally favor the production of pro-inﬂammatory adipokines
regardless of depot site location [47–49]. Interestingly, studies in
mice suggest that aging in the absence of diet-induced obesity
also induces the expression of proinﬂammatory adipokines, such
as TNF and IL-6 in visceral adipose tissue [50,51].
Most adipokines identiﬁed to date are pro-inﬂammatory and
they are upregulated in the obese state. Under conditions of obesity,
these adipokines function to promote metabolic and cardiovas-
cular diseases. Pro-inﬂammatory adipokines include TNF leptin,
IL-6, resistin, RBP4, lipocalin 2, IL-18, ANGPTL2, and others. Here,
as examples, we will only discuss TNF and leptin, but a partial
list of other pro-inﬂammatory adipokines and their cardiovascu-
lar actions can be found in Table 1 and Ref. [52]. In addition to
the numerous pro-inﬂammatory adipokines, adipose tissue also
secretes a smaller number of anti-inﬂammatory factors. These
factors include adiponectin, that has been the subject of intense
investigation [53,54], and SFRP5, that has been recently identiﬁed
as an adipokine with anti-inﬂammatory activities [55].
In this regard, it is difﬁcult to discern whether the increase
in cardiovascular disease associated with an adipokine imbalance
is due to a paracrine mechanism, i.e. the local release of pro-
inﬂammatory factors from epicardial or perivascular adipose tissue,
or an endocrine mechanism that is reﬂected by an increase in
serum adipokine levels. One study that shed light on this ques-
tion performed experiments involving perivascular adipose tissue
transplantation between lean and obese mice [56]. This study pro-
vided evidence that the perivascular location of adipose tissue is
critical in its ability to promote pathological vascular remodeling
and that these effects could be attributed to alterations in the levels
of adiponectin, an adipokine that will be discussed later.
Pro-inﬂammatory adipokine TNF
TNF is a pro-inﬂammatory cytokine that is predominantly
produced by monocytes/macrophages and is involved in many
inﬂammatory diseases. In 1993, TNF was  found to be induced
in adipose tissue in models of diabetes and obesity, providing the
initial evidence for a link between inﬂammation and obesity [57].
TNF expression is upregulated in the adipose tissue and the serum
of patients with obesity, whereas weight loss in obese individuals
K. Nakamura et al. / Journal of Cardiology 63 (2014) 250–259 253
Table  1
Adipokines and cardiovascular function.
Adipokine Inﬂammation Cardiovascular function(s) Reference
Leptin Pro-inﬂammatory See text
Resistin Pro-inﬂammatory Pro-atherogenic, subclinical marker of atherosclerosis, marker of heart failure, predictive of MI  and stroke risk [168–176]
RBP4 Pro-inﬂammatory subclinical marker of atherosclerosis [177–181]
Lipocalin2 Pro-inﬂammatory Unknown [182,183]
ANGPTL2 Pro-inﬂammatory Unknown [184]
TNF Pro-inﬂammatory See text
IL-6 Pro-inﬂammatory Pro-atherogenic, predictive of MI  risk [185–187]
Adiponectin Anti-inﬂammatory See text
SFRP5 Anti-inﬂammatory See text
















































lOmentin Anti-inﬂammatory Pro-angiogenic, inhibition of vascular in
BP4, retinol-binding protein4; ANGPT2, angiopoietin-like protein2; TNF, tumor ne
s associated with a decrease in TNF levels [58,59]. TNF levels
lso correlate with insulin resistance [60]. Mechanistically, TNF
ontributes to insulin resistance by inhibiting the activating phos-
horylation of the insulin receptor and insulin receptor substrate
 (IRS1) in muscle and adipose tissues [61]. In animal models of
besity, the inhibition of TNF leads to an enhancement of insulin
ignaling in muscle and adipose tissue [57,61,62].
TNF has numerous pathophysiological roles in the cardio-
ascular system. TNF levels are increased by acute and chronic
schemic injuries and under conditions of heart failure in humans
s well as animals [63]. As with obesity, aging is associated with a
hronic low-grade increase in TNF levels [50,64]. TNF acts on
onocytes/macrophages, vascular endothelial cells, and smooth
uscle cells to induce the expression of many pro-inﬂammatory,
ro-coagulant, and proliferative genes, contributing to atheroscle-
osis development in animal models [63,65–69]. In vascular smooth
uscle cells, TNF induces migration, proliferation, and apoptosis
70–72], which are cellular processes of major relevance in vascu-
ar pathologies. TNF also induces the rapid expression of adhesion
olecules such as E-selectin, vascular cell adhesion molecule-1,
nd ICAM-1 in endothelial cells [63,73].
TNF can have deleterious or beneﬁcial effects on the heart in
odels of ischemia-reperfusion injury and heart failure depend-
ng on the amount of TNF and the duration of exposure [63,74].
tudies aimed at investigating the effects of TNF neutralization
or the treatment of cardiac disease have led to inconsistent results
n experimental models and clinical trials. Some, but not all, animal
tudies have demonstrated that TNF neutralization or blockade of
NF receptor (TNFR) can attenuate myocardial damage in animal
odels of ischemia/reperfusion and heart failure [63]. In contrast,
ost clinical studies have failed to document the efﬁcacy of TNF
ntagonists [63]. The potential reasons for these discrepant ﬁnd-
ngs are manifold. Contributing to this complexity, TNF exerts its
ffects via two  different receptors, TNFR1 and TNFR2, which exhibit
ifferent patterns of expression and induce distinct signaling path-
ays and cellular processes. TNFR1 is constitutively expressed in
ost cell types except erythrocytes, whereas expression of TNFR2
s highly regulated and is typically higher in immune cells [75,76].
oth the pro-inﬂammatory and the proapoptotic actions of TNF
re largely mediated through TNFR1. In contrast, TNFR2 mediates
he activation of the protective JAK/STAT3 pathway and is believed
o promote tissue repair and angiogenesis [63,76].
ole of leptin in metabolic and cardiovascular disease
The adipokine leptin is the product of the obese gene (ob),
hat was identiﬁed in ob/ob mice through positional cloning
77]. Leptin regulates feeding behavior, and mice that lack lep-
in show hyperphagia, obesity, and insulin resistance. The delivery
f leptin to ob/ob mice reverses these phenotypes [78]. Notably,
eptin has been shown to be effective at improving metabolication, subclinical marker of atherosclerosis [189,190]
 factor; IL, interleukin; MI,  myocardial infarction.
dysfunction in patients with lipodystrophy or congenital leptin
deﬁciency [79,80]. However, circulating leptin levels typically cor-
relate with adipose tissue mass, and obese humans and rodents
have elevated levels of leptin without the expected anorexic
responses [78], suggesting that leptin resistance is common in obe-
sity. A number of mechanisms may  contribute to leptin resistance.
The anorexic effects of leptin result from its actions in the hypo-
thalamus, which are mediated by its binding to the leptin receptor
b (LRb) and the activation of JAK2/STAT3 signaling. In obesity, this
signaling pathway is blocked through different mechanisms, lead-
ing to leptin resistance. One of the major cellular mechanisms
contributing to this phenomenon is the STAT3-mediated induction
of the inhibitory suppressor of cytokine signaling 3 (SOCS3) protein,
which binds the phosphorylated Tyr985 residue in LRb, impairing
leptin-induced signaling [81,82]. Conclusive evidence from ani-
mal  studies supports a primary role for SOCS3 in leptin resistance
[83,84]. Additional mechanisms may  include LRb binding to the
tyrosine phosphatase SHP-2, and activation of the tyrosine phos-
phatase PTP1B, which dephosphorylates Jak2 and thus diminishes
LRb signaling (reviewed in [85]). In addition, it has been suggested
that obesity-induced endoplasmic reticulum stress in the hypothal-
amus also plays a central role in leptin resistance [86].
Leptin is structurally similar to the helical cytokine family that
includes IL-2. Inﬂammatory stimuli increase leptin levels in adi-
pose tissue and in serum [87] and leptin acts on multiple types of
immune cells, such as monocytes/macrophages, neutrophils, and
T cells, to promote the release of inﬂammatory cytokines [88–91].
In T cells, leptin speciﬁcally increases the production of TH1-type
cytokines, and suppresses production of the TH2-type cytokine IL-4
[88], thereby polarizing T cells toward a TH1 cell phenotype. Con-
sistent with these observations, leptin deﬁciency protects against
liver damage in models of T cell-mediated hepatitis and autoim-
mune encephalomyelitis [88,92,93]. Thus, it is generally accepted
that leptin acts as a pro-inﬂammatory adipokine.
Numerous studies have indicated that leptin plays an important
role in cardiovascular diseases. In humans, circulating leptin levels
are increased after myocardial infarction [94]. Similarly, leptin lev-
els are also increased in heart failure patients independent of body
mass [95], and mechanical unloading reverses this increase [96].
Leptin-deﬁcient mice display greater cardiac hypertrophy [97],
increased mortality in a model of viral myocarditis [98], and greater
cardiac remodeling in response to chronic ischemic injury [99].
Leptin receptor deﬁciency also leads to a reduction in ischemia-
induced revascularization that is associated with the impaired
induction of angiogenesis-regulatory factors in the ischemic tissue
[100]. In many of these cases, it has been shown that leptin repletion
can reverse the deleterious effects of leptin deﬁciency. However, it
is difﬁcult to ascertain whether leptin depletion or repletion has a
direct impact on these changes in cardiovascular function because
these manipulations also affect feeding behavior, adipose tis-
sue mass, and numerous systemic metabolic properties. Whereas
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eptin can activate protective JAK-STAT and AMPK signaling path-
ays in cardiovascular tissues, the interpretation of experimental
tudies on leptin that employ ob/ob mice or diet-induced obese
ice are difﬁcult to interpret due to secondary metabolic defects
hat result from hyperphagia (e.g. hyperglycemia, hyperinsuline-
ia, insulin resistance) or the development of leptin resistance,
espectively. Therefore, studies of cardiovascular disease in mice
here the leptin receptor is conditionally ablated in speciﬁc car-
iac, vascular, or immune cell types may  be required to deﬁnitely
ddress these issues.
he anti-inﬂammatory adipokine adiponectin
Adiponectin (also known as ACRP30, AdipoQ, and apM1)
as identiﬁed as an adipocyte-speciﬁc adipokine approximately
5 years ago [101–103]. Adiponectin typically circulates at
igh levels (3–30 g/ml) in the blood [104], and is markedly
ownregulated in obese human subjects. Furthermore, plasma
diponectin level is a good predictor of the risk of type 2 dia-
etes [105,106]. Adiponectin is synthesized at highest levels by
unctional adipocytes found in lean organisms but its expression is
ownregulated in the dysfunctional adipocytes that are associated
ith obesity. Consistent with this notion, adiponectin expression
y adipocytes is inhibited by pro-inﬂammatory cytokines, hypoxia,
nd oxidative stress [53,105,106], conditions associated with the
dipose tissue milieu of obese organisms.
Evidence from experimental models indicates that adiponectin
rotects against obesity-linked metabolic disease. The acute
dministration of adiponectin leads to an improvement in
etabolic parameters in a mouse model of obesity [107].
onversely, adiponectin-deﬁcient mice develop greater insulin
esistance when placed on a high calorie diet [108,109], whereas
he transgenic overexpression of adiponectin in ob/ob mice
mproves metabolic parameters independently of weight loss
110]. The beneﬁcial effects of adiponectin on insulin sensitiv-
ty appear to be mediated in part by its ability to activate AMPK
ignaling axis in metabolically important tissues [111,112]. AMPK
ctivation by adiponectin is thought to involve its interaction with
he cell surface receptors adiponectin receptor 1 and adiponectin
eceptor 2 (AdipoR1 and AdipoR2, respectively) [113–115]. In addi-
ion, studies suggest that the actions of adiponectin may  also be
ediated through additional receptors including PAQR3 (renamed
dipoR3) [116], AdipoRX [117], and T-cadherin [118].
Many lines of evidence show that adiponectin has anti-
nﬂammatory functions. Plasma adiponectin levels are negatively
orrelated with patient CRP levels [104], and adiponectin-deﬁcient
ice have higher levels of TNF in adipose tissue and blood [108].
espite morbid obesity, transgenic overexpression of adiponectin
n ob/ob mice leads to marked improvement in glucose metabolism,
hich is accompanied by reductions in macrophage inﬁltration and
NF expression in adipose tissue [110]. Adiponectin-mediated
odulation of macrophage phenotype contributes to its role in
ontrolling inﬂammation. Macrophages isolated from adiponectin-
eﬁcient mice show increased expression of pro-inﬂammatory
1 markers and decreased expression of anti-inﬂammatory M2
arkers [119]. Conversely, the overexpression of adiponectin in
ice stimulates macrophage M2  marker expression. Adiponectin
nhibits the transformation of macrophages into foam cells by
educing intracellular cholesteryl ester content [120]. Adiponectin
lso inhibits Toll-like receptor-mediated nuclear factor-B activa-
ion and stimulates production of the anti-inﬂammatory cytokine
L-10 by macrophages [121,122]. Given the importance of TNF
xpression and macrophage inﬁltration in adipose tissue dys-
unction [13,14,57], the ability of adiponectin to suppress thesediology 63 (2014) 250–259
pro-inﬂammatory events may  be an important feature in its ability
to prevent obesity-associated metabolic dysfunction.
Adiponectin is structurally similar to the collectin family of pro-
teins that include complement factor C1q and surfactant proteins
A and D. Similar to these abundantly expressed collectin proteins,
adiponectin can form high molecular mass oligomers through its
ability to multimerize via interactions through its collagen-like
domain [53,105]. A property shared by many collectin proteins is
their ability to bind to apoptotic cells and facilitate their uptake by
macrophages, a feature that is also exhibited by adiponectin [123].
Macrophages in adiponectin-deﬁcient mice display a reduced abil-
ity to clear apoptotic debris when challenged by an overload of
dead cells. Because phagocytosis of early apoptotic cells will pro-
mote an M2-like phenotype in macrophages [124], these data
suggest adiponectin’s collectin-like function contributes to its anti-
inﬂammatory actions. Finally, it should be noted that adiponectin
levels are elevated in autoimmune and chronic inﬂammatory dis-
eases [125]. While the molecular basis for adiponectin upregulation
under these conditions is unknown, it may  represent a compen-
satory response because adiponectin has been shown to ameliorate
auto-immunity in a mouse model of lupus [126,127].
Cardiovascular effects of adiponectin. Low serum levels of
adiponectin have been associated with coronary artery disease
[128], hypertension [129], left ventricular hypertrophy [130], and
a greater risk of myocardial infarction [131]. Numerous exper-
imental studies have shown that adiponectin exerts protective
actions on cardiovascular cell types including vascular endothelial
cells, smooth muscle cells, and cardiac myocytes, and adiponectin-
deﬁcient mice display worse outcomes in various models of
cardiovascular disease. Importantly, mouse models of adiponectin-
deﬁciency display normal body and fat mass and normal metabolic
parameters when fed a normal chow diet. Thus, the cardiovas-
cular actions of adiponectin can be studied independently of its
metabolic regulatory effects.
Adiponectin has been shown to exert many vasculoprotec-
tive and angiogenic properties. Studies with adiponectin-deﬁcient
mice have demonstrated that adiponectin promotes revascu-
larization of ischemic limbs [132,133], and protects against
cerebral ischemia-reperfusion [134]. Furthermore, adiponectin
inhibits experimental injury-induced neointimal hyperplasia
[135]. Adiponectin-deﬁcient mice also develop enhanced salt-
induced hypertension due in part to a reduction of endothelial
nitric oxide synthase (eNOS) activity [136], and display impaired
endothelial cell-dependent vasodilatory responses when fed an
atherogenic diet [137]. Finally, some studies, but not all, have
shown that adiponectin overexpression inhibits atherosclerotic
lesion formation, whereas adiponectin-deﬁciency leads to aug-
mented atherosclerosis [138–141]. Mechanistically, many of these
protective actions of adiponectin are linked to its beneﬁcial effects
on endothelial cell function, which are mediated to a great extent
by its ability to stimulate NO production through AMPK-dependent
activation of eNOS [142–144]. In addition, adiponectin induces
the expression of PGI2–an autacoid that promotes vascular func-
tion [145]–and prevents TNF-induced endothelial cell activation
[146,147]. Furthermore, adiponectin has been shown to inhibit pro-
liferation and migration of vascular smooth muscle cells through
direct inhibition of PDGF-BB [148], and to promote the differentia-
tion of vascular smooth muscle cells via repression of mammalian
target of rapamycin complex 1 (mTORC1) and FoxO4 [149].
Various studies have evaluated adiponectin’s actions on the
heart. Adiponectin inhibits pressure overload or angiotensin II-
induced cardiac hypertrophy, at least in part, through its ability to
activate AMPK signaling in myocytes [132,150]. Adiponectin pro-
tects the heart from ischemic reperfusion injury [151,152], and it
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While AdipoR1 and AdipoR2 are widely accepted as the main
eceptors accountable for the metabolic actions of adiponectin
113,114], few studies have investigated adiponectin receptors in
ardiovascular tissues. In this regard, T-cadherin, a GPI-anchored
diponectin-binding protein [118], was recently shown to be
ssential for the cardioprotective and pro-revascularization actions
f adiponectin [155,156]. T-cadherin is highly expressed in the
lasma membrane of heart, skeletal muscle, and vascular tis-
ue [157], where it co-localizes with adiponectin [155,156]. Of
ote, T-cadherin-deﬁcient mice phenocopy adiponectin-deﬁcient
ice in experimental models of chronic and acute cardiac injury
155] and chronic limb ischemia [156], strongly supporting the
ole of T-cadherin in mediating the effects of adiponectin in
he cardiovascular system. While T-cadherin lacks an intracel-
ular domain and thus is unlikely to have a direct effect on
ntracellular signaling, it has been proposed to be essential for
he recruitment of adiponectin to cardiovascular tissues. Suppor-
ing this notion, adiponectin is absent from the heart, vascular
ndothelium, and skeletal muscle in T-cadherin-deﬁcient mice
155,156,158]. In addition, T-cadherin-deﬁcient mice exhibit sig-
iﬁcantly elevated serum levels of adiponectin, further supporting
he impaired recruitment of adiponectin to cardiovascular tis-
ues in these mice. Conversely, adiponectin-deﬁcient mice have
educed tissue expression of T-cadherin suggesting a regulatory
xis between these proteins [155,156,158].
frp5
A recent study has identiﬁed Sfrp5, a soluble modulator of Wnt
roteins, as an adipokine with anti-inﬂammatory properties that
rotects against metabolic dysfunction [55]. Sfrp5 is expressed at
ighest levels in white adipose tissue of mice. Its expression in adi-
ose tissue is down-regulated in various models of rodent obesity
nd in the visceral adipose tissue of metabolically dysfunctional
bese patients that display crown-like structures. Sfrp5 functions
o antagonize noncanonical Wnt5a signaling. Wnt5a is upregulated
n fat depots of obese rodents and, as discussed below, it functions
o promote inﬂammatory responses involving macrophages.
Sfrp5-deﬁcient mice are metabolically normal when maintained
n a regular diet, but display impaired glucose metabolism and
ncreased fatty liver disease when fed a high caloric diet [55].
he enhanced metabolic dysfunction caused by Sfrp5-deﬁciency
s associated with an increased adipose tissue accumulation
f macrophages and increased production of pro-inﬂammatory
ytokines. Mechanistically, Sfrp5 functions to suppress Wnt5a-
ediated activation of JUN N-terminal kinase 1 (JNK1) in adipose
issue, and deletion of JNK1 in Sfrp5-deﬁcient mice reverses
he metabolic and inﬂammatory phenotypes. Thus, the increases
n obesity-induced adipose tissue inﬂammation and metabolic
ysfunction caused by overactivation of JNK1 signaling in Sfrp5-
eﬁcient mice, consistent with the well-described role for JNK1 in
egulating insulin resistance and fat inﬂammation [159–162].
The role of the Sfrp5/Wnt5a regulatory system in cardiovascular
isease is relatively unexplored, but a number of recent studies sug-
est that this may  be an interesting area of investigation. It has been
hown that Wnt5a functions as a macrophage effector molecule
hat promotes inﬂammation in response to microbial infection
ia the activation of noncanonical Wnt  signaling [163,164]. With
egard to cardiovascular actions, Wnt5a promotes inﬂammation
n endothelial cells [165], and noncanonical Wnt5a signaling has
een shown to suppress angiogenesis through the upregulation
f Flt1, an endogenous VEGF inhibitor produced by myeloid cells
166]. Finally, Wnt5a expression has been detected in mouse and
uman atherosclerotic lesions [165,167]. Thus, it is tempting to
peculate that Sfrp5 deﬁciency, as occurs in obesity, leads todiology 63 (2014) 250–259 255
runaway Wnt5a signaling favoring a chronic inﬂammatory state
that promotes cardiovascular disease. Further studies are required
to deﬁnitively address the role of Sfrp5/Wnt5a signaling in regula-
tion of obesity-linked inﬂammatory cardiovascular disorders.
Conclusions
Adipose tissues produce various adipokines that function to
regulate the microenvironment of adipose tissue and communi-
cate with the brain, heart, vasculature, liver, and muscle. These
adipokines have either pro-inﬂammatory or anti-inﬂammatory
activities, and their balance is critical in maintaining systemic
homeostasis. Obesity-induced adipose tissue dysfunction leads to
dysregulated adipokine production that has both local and systemic
effects on inﬂammatory cells. This adipokine imbalance leads to
the development of a low-grade, chronic inﬂammatory state that
contributes to the development of metabolic and cardiovascular
diseases.
Funding sources
Funded by the U.S. National Institutes of Health grants
(AG34972, HL86785, AG15052, and HL81587) to KW.  JJF was  sup-





[1] Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Preva-
lence of overweight and obesity among US children, adolescents, and adults,
1999–2002. JAMA 2004;291:2847–50.
[2] Flegal KM,  Carroll MD,  Kit BK, Ogden CL. Prevalence of obesity and trends
in  the distribution of body mass index among US adults, 1999–2010. JAMA
2012;307:491–7.
[3] Flegal KM,  Carroll MD,  Ogden CL, Curtin LR. Prevalence and trends in obesity
among US adults, 1999–2008. JAMA 2010;303:235–41.
[4] Hirsch J, Batchelor B. Adipose tissue cellularity in human obesity. Clin
Endocrinol Metab 1976;5:299–311.
[5] Hausman DB, DiGirolamo M,  Bartness TJ, Hausman GJ, Martin RJ. The biology
of  white adipocyte proliferation. Obes Rev 2001;2:239–54.
[6] Sun K, Kusminski CM,  Scherer PE. Adipose tissue remodeling and obesity.
J  Clin Invest 2011;121:2094–101.
[7] Faust IM,  Johnson PR, Stern JS, Hirsch J. Diet-induced adipocyte num-
ber increase in adult rats: a new model of obesity. Am J Physiol
1978;235:E279–86.
[8] Cartwright MJ, Tchkonia T, Kirkland JL. Aging in adipocytes: potential impact
of  inherent, depot-speciﬁc mechanisms. Exp Gerontol 2007;42:463–71.
[9] Engfeldt P, Arner P. Lipolysis in human adipocytes, effects of cell size, age and
of  regional differences. Horm Metab Res Suppl 1988;19:26–9.
[10] Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier
M,  Greenberg AS, Obin MS.  Adipocyte death deﬁnes macrophage localiza-
tion  and function in adipose tissue of obese mice and humans. J Lipid Res
2005;46:2347–55.
[11] Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M,  Cinti
S.  Dead adipocytes, detected as crown-like structures, are prevalent in visceral
fat depots of genetically obese mice. J Lipid Res 2008;49:1562–8.
[12] Strissel KJ, Stancheva Z, Miyoshi H, Perﬁeld 2nd JW,  DeFuria J, Jick Z, Green-
berg AS, Obin MS. Adipocyte death, adipose tissue remodeling, and obesity
complications. Diabetes 2007;56:2910–8.
[13] Weisberg SP, McCann D, Desai M, Rosenbaum M,  Leibel RL, Ferrante Jr AW.
Obesity is associated with macrophage accumulation in adipose tissue. J Clin
Invest 2003;112:1796–808.
[14] Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A,
Ross JS, Tartaglia LA, Chen H. Chronic inﬂammation in fat plays a crucial
role in the development of obesity-related insulin resistance. J Clin Invest
2003;112:1821–30.
[15] Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in
adipose tissue macrophage polarization. J Clin Invest 2007;117:175–84.
[16] Gordon S. Alternative activation of macrophages. Nat Rev Immunol
2003;3:23–35.
[17] Odegaard JI, Chawla A. Alternative macrophage activation and metabolism.
Annu Rev Pathol 2011;6:275–97.
2  of Car56 K. Nakamura et al. / Journal
[18] Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM,  Neels JG. Ablation of
CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant
animals. Cell Metab 2008;8:301–9.
[19] Apovian CM,  Bigornia S, Mott M,  Meyers MR,  Ulloor J, Gagua M, McDonnell M,
Hess D, Joseph L, Gokce N. Adipose macrophage inﬁltration is associated with
insulin resistance and vascular endothelial dysfunction in obese subjects.
Arterioscler Thromb Vasc Biol 2008;28:1654–9.
[20] Feuerer M,  Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldﬁne
AB, Benoist C, Shoelson S, Mathis D. Lean, but not obese, fat is enriched for a
unique population of regulatory T cells that affect metabolic parameters. Nat
Med  2009;15:930–9.
[21] Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang
Y,  Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D,
Dosch HM.  Normalization of obesity-associated insulin resistance through
immunotherapy. Nat Med  2009;15:921–9.
[22] Nishimura S, Manabe I, Nagasaki M,  Eto K, Yamashita H, Ohsugi M,  Otsu M,
Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R. CD8+ effector T
cells contribute to macrophage recruitment and adipose tissue inﬂammation
in  obesity. Nat Med  2009;15:914–20.
[23] Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, David-
son MG,  Alonso MN,  Leong HX, Glassford A, Caimol M,  Kenkel JA, Tedder TF,
et al. B cells promote insulin resistance through modulation of T cells and
production of pathogenic IgG antibodies. Nat Med  2011;17:610–7.
[24] Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, Sukhova GK, Wolters
PJ, Du J, Gorgun CZ, Doria A, Libby P, Blumberg RS, Kahn BB, Hotamisligil
GS,  et al. Genetic deﬁciency and pharmacological stabilization of mast cells
reduce diet-induced obesity and diabetes in mice. Nat Med 2009;15:940–5.
[25] Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M,  Li P, Yan Q,
Zhu Y, Ofrecio J, Lin M,  Brenner MB,  Olefsky JM.  Neutrophils mediate insulin
resistance in mice fed a high-fat diet through secreted elastase. Nat Med
2012;18:1407–12.
[26] Mansuy-Aubert V, Zhou QL, Xie X, Gong Z, Huang JY, Khan AR, Aubert G, Can-
delaria K, Thomas S, Shin DJ, Booth S, Baig SM,  Bilal A, Hwang D, Zhang H, et al.
Imbalance between neutrophil elastase and its inhibitor alpha1-antitrypsin
in  obesity alters insulin sensitivity, inﬂammation, and energy expenditure.
Cell Metab 2013;17:534–48.
[27] Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK,
Chawla A, Locksley RM.  Eosinophils sustain adipose alternatively activated
macrophages associated with glucose homeostasis. Science 2011;332:243–7.
[28] Pasarica M,  Sereda OR, Redman LM,  Albarado DC, Hymel DT, Roan LE, Rood JC,
Burk  DH, Smith SR. Reduced adipose tissue oxygenation in human obesity:
evidence for rarefaction, macrophage chemotaxis, and inﬂammation without
an  angiogenic response. Diabetes 2009;58:718–25.
[29] Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inﬂamma-
tion and adiponectin reduction in adipose tissue of ob/ob and dietary obese
mice. Am J Physiol Endocrinol Metab 2007;293:E1118–28.
[30] Pasarica M,  Rood J, Ravussin E, Schwarz JM,  Smith SR, Redman LM.  Reduced
oxygenation in human obese adipose tissue is associated with impaired
insulin suppression of lipolysis. J Clin Endocrinol Metab 2010;95:4052–5.
[31] Gealekman O, Guseva N, Hartigan C, Apotheker S, Gorgoglione M, Gurav
K,  Tran KV, Straubhaar J, Nicoloro S, Czech MP,  Thompson M, Perugini RA,
Corvera S. Depot-speciﬁc differences and insufﬁcient subcutaneous adipose
tissue angiogenesis in human obesity. Circulation 2011;123:186–94.
[32] Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken
JW,  Cajlakovic M,  Ribitsch V, Clement K, Blaak EE. Increased adipose tissue
oxygen tension in obese compared with lean men  is accompanied by insulin
resistance, impaired adipose tissue capillarization, and inﬂammation. Circu-
lation 2011;124:67–76.
[33] Sun K, Asterholm IW,  Kusminski CM,  Bueno AC, Wang ZV, Pollard JW,  Brekken
RA, Scherer PE. Dichotomous effects of VEGF-A on adipose tissue dysfunction.
Proc Natl Acad Sci U S A 2012;109:5874–9.
[34] Elias I, Franckhauser S, Ferre T, Vila L, Tafuro S, Munoz S, Roca C, Ramos D,
Pujol A, Riu E, Ruberte J, Bosch F. Adipose tissue overexpression of vascular
endothelial growth factor protects against diet-induced obesity and insulin
resistance. Diabetes 2012.
[35] Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, Nelson SM,  Cowling R, Nagy K,
Michael IP, Koh GY, Adamson SL, Pawson T, Nagy A. Adipose vascular endothe-
lial growth factor regulates metabolic homeostasis through angiogenesis. Cell
Metab 2013;17:61–72.
[36] Corvera S, Czech MP. Tensions rise and blood ﬂows over dysfunctional fat.
Circulation 2011;124:13–6.
[37] Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W,  Gavrilova O, Shah YM,  Gon-
zalez FJ. Disruption of hypoxia-inducible factor 1 in adipocytes improves
insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes
2011;60:2484–95.
[38] Halberg N, Khan T, Trujillo ME,  Wernstedt-Asterholm I, Attie AD, Sherwani S,
Wang ZV, Landskroner-Eiger S, Dineen S, Magalang UJ, Brekken RA, Scherer
PE. Hypoxia-inducible factor 1alpha induces ﬁbrosis and insulin resistance in
white adipose tissue. Mol  Cell Biol 2009;29:4467–83.
[39] Krishnan J, Danzer C, Simka T, Ukropec J, Walter KM,  Kumpf S, Mirtschink
P,  Ukropcova B, Gasperikova D, Pedrazzini T, Krek W.  Dietary obesity-
associated Hif1alpha activation in adipocytes restricts fatty acid oxidation
and energy expenditure via suppression of the Sirt2-NAD+ system. Genes
Dev 2012;26:259–70.
[40] Zhang X, Lam KS, Ye H, Chung SK, Zhou M,  Wang Y, Xu A. Adipose tissue-
speciﬁc inhibition of hypoxia-inducible factor 1{alpha} induces obesity anddiology 63 (2014) 250–259
glucose intolerance by impeding energy expenditure in mice. J Biol Chem
2010;285:32869–77.
[41] Nishimura S, Manabe I, Nagasaki M,  Seo K, Yamashita H, Hosoya Y, Ohsugi
M,  Tobe K, Kadowaki T, Nagai R, Sugiura S. In vivo imaging in mice reveals
local cell dynamics and inﬂammation in obese adipose tissue. J Clin Invest
2008;118:710–21.
[42] Hotamisligil GS. Inﬂammation and metabolic disorders. Nature
2006;444:860–7.
[43] Shoelson SE, Lee J, Goldﬁne AB. Inﬂammation and insulin resistance. J Clin
Invest 2006;116:1793–801.
[44] Visser M,  Bouter LM, McQuillan GM, Wener MH,  Harris TB. Elevated C-reactive
protein levels in overweight and obese adults. JAMA 1999;282:2131–5.
[45] Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM.  C-reactive pro-
tein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA
2001;286:327–34.
[46] Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M,  Marfella R, Giugliano
D.  Effect of weight loss and lifestyle changes on vascular inﬂammatory mark-
ers in obese women: a randomized trial. JAMA 2003;289:1799–804.
[47] Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adi-
pose tissue gene expression of serum adipokines that predict type 2 diabetes.
Obesity (Silver Spring) 2010;18:884–9.
[48] Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tis-
sues of obese subjects release interleukin-6: depot difference and regulation
by  glucocorticoid. J Clin Endocrinol Metab 1998;83:847–50.
[49] Chatterjee TK, Stoll LL, Denning GM,  Harrelson A, Blomkalns AL, Idelman G,
Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW,  Rudich S, Weintraub
NL. Proinﬂammatory phenotype of perivascular adipocytes: inﬂuence of high-
fat  feeding. Circ Res 2009;104:541–9.
[50] Wu D, Ren Z, Pae M,  Guo W,  Cui X, Merrill AH, Meydani SN. Aging up-regulates
expression of inﬂammatory mediators in mouse adipose tissue. J Immunol
2007;179:4829–39.
[51] Starr ME,  Evers BM,  Saito H. Age-associated increase in cytokine production
during systemic inﬂammation: adipose tissue as a major source of IL-6. J
Gerontol A Biol Sci Med  Sci 2009;64:723–30.
[52] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inﬂammation and
metabolic disease. Nat Rev Immunol 2011;11:85–97.
[53] Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin
and vascular inﬂammatory disease. Curr Opin Lipidol 2003;14:561–6.
[54] Berg AH, Scherer PE. Adipose tissue, inﬂammation, and cardiovascular dis-
ease. Circ Res 2005;96:939–49.
[55] Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R, Akasaki Y,
Shimono A, Walsh K. Sfrp5 is an anti-inﬂammatory adipokine that modulates
metabolic dysfunction in obesity. Science 2010;329:454–7.
[56] Takaoka M,  Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y,
Nagai R, Sata M.  Periadventitial adipose tissue plays a critical role in vascular
remodeling. Circ Res 2009;105:906–11.
[57] Hotamisligil GS, Shargill NS, Spiegelman BM.  Adipose expression of tumor
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science
1993;259:87–91.
[58] Kern PA, Saghizadeh M,  Ong JM,  Bosch RJ, Deem R, Simsolo RB. The expres-
sion  of tumor necrosis factor in human adipose tissue. Regulation by
obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest
1995;95:2111–9.
[59] Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Ciofﬁ M,  D’Andrea
F, Molinari AM,  Giugliano D. Reduction of inﬂammatory cytokine concentra-
tions and improvement of endothelial functions in obese women after weight
loss over one year. Circulation 2002;105:804–9.
[60] Hivert MF,  Sullivan LM,  Fox CS, Nathan DM,  D’Agostino Sr RB, Wilson
PW,  Meigs JB. Associations of adiponectin, resistin, and tumor necro-
sis  factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008;93:
3165–72.
[61] Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine
kinase activity of the insulin receptor in obesity-diabetes. Central role of
tumor necrosis factor-alpha. J Clin Invest 1994;94:1543–9.
[62] Uysal KT, Wiesbrock SM,  Marino MW,  Hotamisligil GS. Protection from
obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature
1997;389:610–4.
[63] Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial
ischemia/reperfusion and heart failure. Pharmacol Ther 2010;127:295–314.
[64] Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Age-
ing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp
Immunol 2000;121:255–60.
[65] Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa
K, Seishima M.  Disruption of tumor necrosis factor-alpha gene diminishes
the development of atherosclerosis in ApoE-deﬁcient mice. Atherosclerosis
2005;180:11–7.
[66] Bergh N, Ulfhammer E, Glise K, Jern S, Karlsson L. Inﬂuence of TNF-alpha and
biomechanical stress on endothelial anti- and prothrombotic genes. Biochem
Biophys Res Commun 2009;385:314–8.
[67] Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ,  de Winther
MP,  Havekes LM,  van Vlijmen BJ. Tumor necrosis factor-alpha promotes
atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardio-
vasc Res 2005;66:179–85.
[68] Branen L, Hovgaard L, Nitulescu M,  Bengtsson E, Nilsson J, Jovinge S. Inhibition
of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E
knockout mice. Arterioscler Thromb Vasc Biol 2004;24:2137–42.
 of CarK. Nakamura et al. / Journal
[69] Xiao N, Yin M, Zhang L, Qu X, Du H, Sun X, Mao L, Ren G, Zhang C, Geng Y, An L,
Pan J. Tumor necrosis factor-alpha deﬁciency retards early fatty-streak lesion
by inﬂuencing the expression of inﬂammatory factors in apoE-null mice. Mol
Genet Metab 2009;96:239–44.
[70] Boyle JJ, Weissberg PL, Bennett MR.  Tumor necrosis factor-alpha pro-
motes macrophage-induced vascular smooth muscle cell apoptosis by
direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003;23:
1553–8.
[71] Goetze S, Kintscher U, Kaneshiro K, Meehan WP,  Collins A, Fleck E, Hsueh WA,
Law RE. TNFalpha induces expression of transcription factors c-fos, Egr-1, and
Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2.
Atherosclerosis 2001;159:93–101.
[72] Goetze S, Xi XP, Kawano Y, Kawano H, Fleck E, Hsueh WA,  Law RE. TNF-
alpha-induced migration of vascular smooth muscle cells is MAPK dependent.
Hypertension 1999;33:183–9.
[73] Slowik MR,  De Luca LG, Fiers W,  Pober JS. Tumor necrosis factor activates
human endothelial cells through the p55 tumor necrosis factor receptor but
the p75 receptor contributes to activation at low tumor necrosis factor con-
centration. Am J Pathol 1993;143:1724–30.
[74] Kleinbongard P, Schulz R, Heusch G. TNFalpha in myocardial
ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev
2011;16:49–69.
[75] Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM.  Sex-related sur-
vival differences in murine cardiomyopathy are associated with differences
in  TNF-receptor expression. J Clin Invest 2000;106:589–97.
[76] Wajant H, Pﬁzenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell
Death Differ 2003;10:45–65.
[77] Zhang Y, Proenca R, Maffei M,  Barone M,  Leopold L, Friedman JM.  Posi-
tional cloning of the mouse obese gene and its human homologue. Nature
1994;372:425–32.
[78] Friedman JM.  Leptin, leptin receptors, and the control of body weight. Nutr
Rev  1998;56:s38–46, discussion s54–75.
[79] Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ,
DePaoli AM,  Reitman ML,  Taylor SI, Gorden P, Garg A. Leptin-replacement
therapy for lipodystrophy. N Engl J Med  2002;346:570–8.
[80] Farooqi IS, Matarese G, Lord GM,  Keogh JM,  Lawrence E, Agwu C, Sanna V,
Jebb  SA, Perna F, Fontana S, Lechler RI, DePaoli AM,  O’Rahilly S. Beneﬁcial
effects of leptin on obesity, T cell hyporesponsiveness, and neuroen-
docrine/metabolic dysfunction of human congenital leptin deﬁciency. J Clin
Invest 2002;110:1093–103.
[81] Bjorbak C, Lavery HJ, Bates SH, Olson RK, Davis SM,  Flier JS, Myers Jr MG.
SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol
Chem 2000;275:40649–57.
[82] Dunn SL, Bjornholm M,  Bates SH, Chen Z, Seifert M,  Myers Jr MG.  Feedback
inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor
and suppressor of cytokine signaling 3. Mol  Endocrinol 2005;19:925–38.
[83] Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C, Flier JS. Enhanced leptin
sensitivity and attenuation of diet-induced obesity in mice with haploinsuf-
ﬁciency of Socs3. Nat Med  2004;10:734–8.
[84] Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu
T,  Chien KR, Yasukawa H, Yoshimura A. Socs3 deﬁciency in the brain ele-
vates leptin sensitivity and confers resistance to diet-induced obesity. Nat
Med  2004;10:739–43.
[85] Myers MG,  Cowley MA,  Munzberg H. Mechanisms of leptin action and leptin
resistance. Annu Rev Physiol 2008;70:537–56.
[86] Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers Jr MG,  Ozcan U.
Endoplasmic reticulum stress plays a central role in development of leptin
resistance. Cell Metab 2009;9:35–51.
[87] Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR.
Endotoxin and cytokines induce expression of leptin, the ob gene product,
in  hamsters. J Clin Invest 1996;97:2152–7.
[88] Lord GM,  Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Lep-
tin  modulates the T-cell immune response and reverses starvation-induced
immunosuppression. Nature 1998;394:897–901.
[89] Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin stimulates
proliferation and activation of human circulating monocytes. Cell Immunol
1999;194:6–11.
[90] Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Leptin enhances
CC-chemokine ligand expression in cultured murine macrophage. Biochem
Biophys Res Commun 2009;384:311–5.
[91] Zarkesh-Esfahani H, Pockley AG, Wu Z, Hellewell PG, Weetman AP, Ross RJ.
Leptin indirectly activates human neutrophils via induction of TNF-alpha. J
Immunol 2004;172:1809–14.
[92] Faggioni R, Jones-Carson J, Reed DA, Dinarello CA, Feingold KR, Grunfeld C,
Fantuzzi G. Leptin-deﬁcient (ob/ob) mice are protected from T cell-mediated
hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad
Sci U S A 2000;97:2367–72.
[93] Matarese G, Di Giacomo A, Sanna V, Lord GM,  Howard JK, Di Tuoro A,
Bloom SR, Lechler RI, Zappacosta S, Fontana S. Requirement for leptin in
the  induction and progression of autoimmune encephalomyelitis. J Immunol
2001;166:5909–16.[94] Fujimaki S, Kanda T, Fujita K, Tamura J, Kobayashi I. The signiﬁcance of
measuring plasma leptin in acute myocardial infarction. J Int Med  Res
2001;29:108–13.
[95] Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M,  Siwik D, Colucci WS.
Dynamics in insulin resistance and plasma levels of adipokines in patientsdiology 63 (2014) 250–259 257
with acute decompensated and chronic stable heart failure. J Card Fail
2011;17:1004–11.
[96] McGafﬁn KR, Moravec CS, McTiernan CF. Leptin signaling in the failing and
mechanically unloaded human heart. Circ Heart Fail 2009;2:676–83.
[97] Barouch LA, Berkowitz DE, Harrison RW,  O’Donnell CP, Hare JM.  Disruption
of  leptin signaling contributes to cardiac hypertrophy independently of body
weight in mice. Circulation 2003;108:754–9.
[98] Kanda T, Takahashi T, Kudo S, Takeda T, Tsugawa H, Takekoshi N. Leptin deﬁ-
ciency enhances myocardial necrosis and lethality in a murine model of viral
myocarditis. Life Sci 2004;75:1435–47.
[99] McGafﬁn KR, Zou B, McTiernan CF, O’Donnell CP. Leptin attenuates cardiac
apoptosis after chronic ischaemic injury. Cardiovasc Res 2009;83:313–24.
[100] Schiekofer S, Galasso G, Sato K, Kraus BJ, Walsh K. Impaired revasculariza-
tion in a mouse model of type 2 diabetes is associated with dysregulation
of  a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol
2005;25:1603–9.
[101] Hu E, Liang P, Spiegelman BM.  AdipoQ is a novel adipose-speciﬁc gene dys-
regulated in obesity. J Biol Chem 1996;271:10697–703.
[102] Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K.
cDNA cloning and expression of a novel adipose speciﬁc collagen-like fac-
tor,  apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res
Commun 1996;221:286–9.
[103] Scherer PE, Williams S, Fogliano M,  Baldini G, Lodish HF. A novel serum
protein similar to C1q, produced exclusively in adipocytes. J Biol Chem
1995;270:26746–9.
[104] Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M,  Kumada M, Okamoto
Y,  Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H,
Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with
adiponectin in blood stream and adipose tissue. Circulation 2003;107:671–4.
[105] Arita Y, Kihara S, Ouchi N, Takahashi M,  Maeda K, Miyagawa J, Hotta K, Shimo-
mura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M,  Yamashita S, Okubo
K,  Matsubara K, et al. Paradoxical decrease of an adipose-speciﬁc protein,
adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
[106] Li S, Shin HJ, Ding EL, van Dam RM.  Adiponectin levels and risk of type 2
diabetes: a systematic review and meta-analysis. JAMA 2009;302:179–88.
[107] Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR,  Yen FT, Bihain BE,
Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-
related protein increases fatty acid oxidation in muscle and causes weight
loss in mice. Proc Natl Acad Sci U S A 2001;98:2005–10.
[108] Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M,  Nagaretani H,
Furuyama N, Kondo H, Takahashi M,  Arita Y, Komuro R, Ouchi N, Kihara S,
Tochino Y, Okutomi K, et al. Diet-induced insulin resistance in mice lacking
adiponectin/ACRP30. Nat Med  2002;8:731–7.
[109] Nawrocki AR, Rajala MW,  Tomas E, Pajvani UB, Saha AK, Trumbauer ME,
Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking
adiponectin show decreased hepatic insulin sensitivity and reduced respon-
siveness to peroxisome proliferator-activated receptor gamma agonists. J Biol
Chem 2006;281:2654–60.
[110] Kim JY, van de Wall E, Laplante M,  Azzara A, Trujillo ME, Hofmann SM,
Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF,  Hui DY, Deshaies Y,
Shulman GI, et al. Obesity-associated improvements in metabolic proﬁle
through expansion of adipose tissue. J Clin Invest 2007;117:2621–37.
[111] Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Rud-
erman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30
globular domain: acetyl-CoA carboxylase inhibition and AMP-activated pro-
tein kinase activation. Proc Natl Acad Sci U S A 2002;99:16309–13.
[112] Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S,
Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P,
et  al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by
activating AMP-activated protein kinase. Nat Med  2002;8:1288–95.
[113] Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T,
Miyagishi M,  Hara K, Tsunoda M,  Murakami K, Ohteki T, Uchida S, Takekawa
S,  Waki H, et al. Cloning of adiponectin receptors that mediate antidiabetic
metabolic effects. Nature 2003;423:762–9.
[114] Yamauchi T, Nio Y, Maki T, Kobayashi M,  Takazawa T, Iwabu M, Okada-Iwabu
M,  Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K,
Kozono H, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abroga-
tion of adiponectin binding and metabolic actions. Nat Med 2007;13:332–9.
[115] Iwabu M,  Yamauchi T, Okada-Iwabu M,  Sato K, Nakagawa T, Funata M, Yam-
aguchi M,  Namiki S, Nakayama R, Tabata M,  Ogata H, Kubota N, Takamoto I,
Hayashi YK, Yamauchi N, et al. Adiponectin and AdipoR1 regulate PGC-1alpha
and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010;464:1313–9.
[116] Garitaonandia I, Smith JL, Kupchak BR, Lyons TJ. Adiponectin identiﬁed as an
agonist for PAQR3/RKTG using a yeast-based assay system. J Recept Signal
Transduct Res 2009;29:67–73.
[117] Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy
longevity and obesity-related diseases. Cell Metab 2013;17:185–96.
[118] Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor
for  hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc
Natl  Acad Sci U S A 2004;101:10308–13.
[119] Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA,
Kalthoff C, Tullin S, Sams A, Summer R, Walsh K. Adiponectin promotes
macrophage polarization toward an anti-inﬂammatory phenotype. J Biol
Chem 2010;285:6153–60.
[120] Ouchi N, Kihara S, Arita Y, Nishida M,  Matsuyama A, Okamoto Y, Ishigami
M,  Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y,
2  of Car58 K. Nakamura et al. / Journal
Yamashita S, Funahashi T. Adipocyte-derived plasma protein, adiponectin,
suppresses lipid accumulation and class A scavenger receptor expres-
sion in human monocyte-derived macrophages. Circulation 2001;103:
1057–63.
[121] Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M,  Nonaka K, Saito T,
Hanazawa S, Yamashita Y. Adiponectin inhibits Toll-like receptor family-
induced signaling. FEBS Lett 2005;579:6821–6.
[122] Kumada M,  Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda
K,  Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa
Y.  Adiponectin speciﬁcally increased tissue inhibitor of metalloproteinase-
1  through interleukin-10 expression in human macrophages. Circulation
2004;109:2046–9.
[123] Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT,  Summer RS,
Kihara S, Walsh K. Adiponectin modulates inﬂammatory reactions via cal-
reticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest
2007;117:375–86.
[124] Savill J, Dransﬁeld I, Gregory C, Haslett C. A blast from the past: clear-
ance of apoptotic cells regulates immune responses. Nat Rev Immunol
2002;2:965–75.
[125] Fantuzzi G. Adiponectin in inﬂammatory and immune-mediated diseases.
Cytokine 2013;64:1–10.
[126] Parker J, Menn-Josephy H, Laskow B, Takemura Y, Aprahamian T. Modulation
of  lupus phenotype by adiponectin deﬁciency in autoimmune mouse models.
J Clin Immunol 2011;31:167–73.
[127] Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh
K,  Rifkin IR. The peroxisome proliferator-activated receptor gamma ago-
nist rosiglitazone ameliorates murine lupus by induction of adiponectin. J
Immunol 2009;182:340–6.
[128] Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM,
Danesh J, Whincup PH. Adiponectin and coronary heart disease: a prospective
study and meta-analysis. Circulation 2006;114:623–9.
[129] Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M,  Sugimoto K, Fu Y,
Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi
H, Matsuzawa Y, et al. Hypoadiponectinemia is an independent risk factor for
hypertension. Hypertension 2004;43:1318–23.
[130] Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM.  Associations among plasma
adiponectin, hypertension, left ventricular diastolic function and left ventri-
cular mass index. Blood Press 2004;13:236–42.
[131] Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma
adiponectin levels and risk of myocardial infarction in men. JAMA
2004;291:1730–7.
[132] Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin sti-
mulates angiogenesis in response to tissue ischemia through stimulation of
amp-activated protein kinase signaling. J Biol Chem 2004;279:28670–4.
[133] Kondo M,  Shibata R, Miura R, Shimano M, Kondo K, Li P, Ohashi T, Kihara S,
Maeda N, Walsh K, Ouchi N, Murohara T. Caloric restriction stimulates revas-
cularization in response to ischemia via adiponectin-mediated activation of
endothelial nitric-oxide synthase. J Biol Chem 2009;284:1718–24.
[134] Nishimura M,  Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK,
Moskowitz MA,  Ouchi N. Adiponectin prevents cerebral ischemic injury
through endothelial nitric oxide synthase dependent mechanisms. Circula-
tion 2008;117:216–23.
[135] Matsuda M,  Shimomura I, Sata M,  Arita Y, Nishida M, Maeda N, Kumada
M,  Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N,
Kihara S, Nagai R, et al. Role of adiponectin in preventing vascular stenosis.
The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487–91.
[136] Ohashi K, Kihara S, Ouchi N, Kumada M,  Fujita K, Hiuge A, Hibuse T, Ryo
M,  Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T,
Shimomura I. Adiponectin replenishment ameliorates obesity-related hyper-
tension. Hypertension 2006;47:1108–16.
[137] Li R, Wang WQ,  Zhang H, Yang X, Fan Q, Christopher TA, Lopez BL, Tao
L,  Goldstein BJ, Gao F, Ma  XL. Adiponectin improves endothelial function
in  hyperlipidemic rats by reducing oxidative/nitrative stress and differ-
ential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab
2007;293:E1703–8.
[138] Okamoto Y, Folco EJ, Minami M,  Wara AK, Feinberg MW,  Sukhova GK,
Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P. Adiponectin inhibits
the production of CXC receptor 3 chemokine ligands in macrophages and
reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008;102:
218–25.
[139] Okamoto Y, Kihara S, Ouchi N, Nishida M,  Arita Y, Kumada M, Ohashi K, Sakai
N,  Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa
Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deﬁcient mice.
Circulation 2002;106:2767–70.
[140] Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y,
Takakuwa K, Matsui J, Takata M,  Eto K, Terauchi Y, Komeda K, Tsunoda M,  et al.
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deﬁcient
mice from atherosclerosis. J Biol Chem 2003;278:2461–8.
[141] Nawrocki AR, Hofmann SM,  Teupser D, Basford JE, Durand JL, Jelicks LA, Woo
CW,  Kuriakose G, Factor SM,  Tanowitz HB, Hui DY, Tabas I, Scherer PE. Lack
of  association between adiponectin levels and atherosclerosis in mice. Arte-
rioscler Thromb Vasc Biol 2010;30:1159–65.
[142] Ouchi N, Kobayashi H, Kihara S, Kumada M,  Sato K, Inoue T, Funahashi T, Walsh
K.  Adiponectin stimulates angiogenesis by promoting cross-talk between
AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol
Chem 2004;279:1304–9.diology 63 (2014) 250–259
[143] Chen H, Montagnani M,  Funahashi T, Shimomura I, Quon MJ.  Adiponectin
stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem
2003;278:45021–6.
[144] Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M,  Abe Y, Funahashi T,
Matsuzawa Y. Selective suppression of endothelial cell apoptosis by the high
molecular weight form of adiponectin. Circ Res 2004;94:e27–31.
[145] Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR, Kihara
S,  Walsh K. Adiponectin promotes revascularization of ischemic muscle
through a cyclooxygenase 2-dependent mechanism. Mol  Cell Biol 2009;29:
3487–99.
[146] Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida
M,  Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel
modulator for endothelial adhesion molecules: adipocyte-derived plasma
protein adiponectin. Circulation 1999;100:2473–6.
[147] Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida
M,  Takahashi M,  Muraguchi M,  Ohmoto Y, Nakamura T, Yamashita S, Funa-
hashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein,
inhibits endothelial NF-kappaB signaling through a cAMP-dependent path-
way. Circulation 2000;102:1296–301.
[148] Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M,  Hotta
K, Nishida M,  Takahashi M,  Nakamura T, Shimomura I, Muraguchi M,  Ohmoto
Y,  Funahashi T, et al. Adipocyte-derived plasma protein adiponectin acts as
a  platelet-derived growth factor-BB-binding protein and regulates growth
factor-induced common postreceptor signal in vascular smooth muscle cell.
Circulation 2002;105:2893–8.
[149] Ding M, Xie Y, Wagner RJ, Jin Y, Carrao AC, Liu LS, Guzman AK, Powell RJ, Hwa
J,  Rzucidlo EM,  Martin KA. Adiponectin induces vascular smooth muscle cell
differentiation via repression of mammalian target of rapamycin complex 1
and FoxO4. Arterioscler Thromb Vasc Biol 2011;31:1403–10.
[150] Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori
M,  Matsuzawa Y, Funahashi T, Kitakaze M.  Exacerbation of heart failure in
adiponectin-deﬁcient mice due to impaired regulation of AMPK and glucose
metabolism. Cardiovasc Res 2005;67:705–13.
[151] Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W,
Chan L, Goldstein BJ, Ma XL. Adiponectin cardioprotection after myocardial
ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Cir-
culation 2007;115:1408–16.
[152] Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi
T,  Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-
reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat
Med  2005;11:1096–103.
[153] Sam F, Duhaney TA, Sato K, Wilson RM, Ohashi K, Sono-Romanelli S, Higuchi
A,  De Silva DS, Qin F, Walsh K, Ouchi N. Adiponectin deﬁciency, diastolic
dysfunction, and diastolic heart failure. Endocrinology 2010;151:322–31.
[154] Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS,  Sam
F,  Ouchi N, Walsh K. Adiponectin protects against the development of
systolic dysfunction following myocardial infarction. J Mol  Cell Cardiol
2007;42:1065–74.
[155] Denzel MS,  Scimia MC,  Zumstein PM,  Walsh K, Ruiz-Lozano P, Ranscht B. T-
cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin
Invest 2010;120:4342–52.
[156] Parker-Duffen JL, Nakamura K, Silver M,  Kikuchi R, Tigges U, Yoshida S, Denzel
MS,  Ranscht B, Walsh K. T-cadherin is essential for adiponectin-mediated
revascularization. J Biol Chem 2013;288:24886–97.
[157] Ivanov D, Philippova M,  Antropova J, Gubaeva F, Iljinskaya O, Tararak E,
Bochkov V, Erne P, Resink T, Tkachuk V. Expression of cell adhesion molecule
T-cadherin in the human vasculature. Histochem Cell Biol 2001;115:
231–42.
[158] Hebbard LW,  Garlatti M,  Young LJ, Cardiff RD, Oshima RG, Ranscht B.
T-cadherin supports angiogenesis and adiponectin association with the vas-
culature in a mouse mammary tumor model. Cancer Res 2008;68:1407–16.
[159] Sabio G, Das M,  Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. A
stress signaling pathway in adipose tissue regulates hepatic insulin resistance.
Science 2008;322:1539–43.
[160] Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W,
Grivennikov S, Wynshaw-Boris A, Scadeng M,  Olefsky JM,  Karin M.  JNK1
in hematopoietically derived cells contributes to diet-induced inﬂamma-
tion and insulin resistance without affecting obesity. Cell Metab 2007;6:
386–97.
[161] Vallerie SN, Furuhashi M,  Fucho R, Hotamisligil GS. A predominant role for
parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic
insulin sensitivity. PLoS One 2008;3:e3151.
[162] Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M,
Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature
2002;420:333–6.
[163] Pereira C, Schaer DJ, Bachli EB, Kurrer MO,  Schoedon G. Wnt5A/CaMKII
signaling contributes to the inﬂammatory response of macrophages and is a
target for the antiinﬂammatory action of activated protein C and interleukin-
10. Arterioscler Thromb Vasc Biol 2008;28:504–10.
[164] Blumenthal A, Ehlers S, Lauber J, Buer J, Lange C, Goldmann T, Heine H,
Brandt E, Reiling N. The Wingless homolog WNT5A and its receptor Frizzled-
5 regulate inﬂammatory responses of human mononuclear cells induced by
microbial stimulation. Blood 2006;108:965–73.
[165] Kim J, Kim J, Kim DW,  Ha Y, Ihm MH,  Kim H, Song K, Lee I. Wnt5a induces















[K. Nakamura et al. / Journal
166] Stefater 3rd JA, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J,
Ajima R, Molkentin JD, Williams BO, Wills-Karp M,  Pollard JW,  Yamaguchi T,
Ferrara N, Gerhardt H, et al. Regulation of angiogenesis by a non-canonical
Wnt-Flt1 pathway in myeloid cells. Nature 2011;474:511–5.
167] Christman 2nd MA,  Goetz DJ, Dickerson E, McCall KD, Lewis CJ, Benen-
cia F, Silver MJ, Kohn LD, Malgor R. Wnt5a is expressed in murine and
human atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2008;294:
H2864–70.
168] Burnett MS,  Lee CW,  Kinnaird TD, Stabile E, Durrani S, Dullum MK, Devaney
JM,  Fishman C, Stamou S, Canos D, Zbinden S, Clavijo LC, Jang GJ, Andrews
JA, Zhu J, et al. The potential role of resistin in atherogenesis. Atherosclerosis
2005;182:241–8.
169] Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I,
Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin
on vascular endothelial cells: a new insight into adipocytokine-endothelial
cell interactions. Biochem Biophys Res Commun 2004;314:415–9.
170] Verma S, Li SH, Wang CH, Fedak PW,  Li RK, Weisel RD, Mickle DA. Resistin pro-
motes endothelial cell activation: further evidence of adipokine-endothelial
interaction. Circulation 2003;108:736–40.
171] Robertson SA, Rae CJ, Graham A. Induction of angiogenesis by murine
resistin: putative role of PI3-kinase and NO-dependent pathways. Regul Pept
2009;152:41–7.
172] Mu  H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin
promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res
2006;70:146–57.
173] Weikert C, Westphal S, Berger K, Dierkes J, Mohlig M,  Spranger J, Rimm EB,
Willich SN, Boeing H, Pischon T. Plasma resistin levels and risk of myocardial
infarction and ischemic stroke. J Clin Endocrinol Metab 2008;93:2647–53.
174] Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, Cushman M, Rohan TE,
McGinn AP, Wang T, Strickler HD, Scherer PE, Mackey R, Curb D, Ho GY.
Resistin, but not adiponectin and leptin, is associated with the risk of ischemic
stroke among postmenopausal women: results from the Women’s Health
Initiative. Stroke 2011;42:1813–20.
175] Frankel DS, Vasan RS, D’Agostino Sr RB, Benjamin EJ, Levy D, Wang TJ, Meigs
JB. Resistin, adiponectin, and risk of heart failure the Framingham offspring
study. J Am Coll Cardiol 2009;53:754–62.
176] Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW,  Lee J, Lee HJ, Lee TK, Park J, Hwang
SJ, Kwon YW,  Cho HJ, Oh BH, Park YB, et al. Adipokine resistin is a key player
to  modulate monocytes, endothelial cells, and smooth muscle cells, leading
to  progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol
2011;57:99–109.177] Cabre A, Lazaro I, Girona J, Manzanares J, Marimon F, Plana N, Heras M,  Masana
L.  Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and
cardiovascular disease in type 2 diabetes. J Intern Med  2007;262:496–503.
178] Ingelsson E, Lind L. Circulating retinol-binding protein 4 and subclinical car-
diovascular disease in the elderly. Diabetes Care 2009;32:733–5.diology 63 (2014) 250–259 259
[179] Ingelsson E, Sundstrom J, Melhus H, Michaelsson K, Berne C, Vasan RS,
Riserus U, Blomhoff R, Lind L, Arnlov J. Circulating retinol-binding protein
4,  cardiovascular risk factors and prevalent cardiovascular disease in elderly.
Atherosclerosis 2009;206:239–44.
[180] Mohapatra J, Sharma M,  Acharya A, Pandya G, Chatterjee A, Balaraman R, Jain
MR.  Retinol-binding protein 4: a possible role in cardiovascular complica-
tions. Br J Pharmacol 2011;164:1939–48.
[181] Norseen J, Hosooka T, Hammarstedt A, Yore MM,  Kant S, Aryal P, Kiernan UA,
Phillips DA, Maruyama H, Kraus BJ, Usheva A, Davis RJ, Smith U, Kahn BB.
Retinol-binding protein 4 inhibits insulin signaling in adipocytes by induc-
ing proinﬂammatory cytokines in macrophages through a c-Jun N-terminal
kinase- and toll-like receptor 4-dependent and retinol-independent mecha-
nism. Mol  Cell Biol 2012;32:2010–9.
[182] Yan QW,  Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, Houstis NE, Kahn BB,
Rosen ED. The adipokine lipocalin 2 is regulated by obesity and promotes
insulin resistance. Diabetes 2007;56:2533–40.
[183] Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The role of lipocalin
2  in the regulation of inﬂammation in adipocytes and macrophages. Mol
Endocrinol 2008;22:1416–26.
[184] Tabata M,  Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M,  Urano T, Zhu
HJ, Tsukano H, Tazume H, Kaikita K, Miyashita K, Iwawaki T, Shimabukuro M,
Sakaguchi K, et al. Angiopoietin-like protein 2 promotes chronic adipose tis-
sue inﬂammation and obesity-related systemic insulin resistance. Cell Metab
2009;10:178–88.
[185] Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F.
Involvement of interleukin-6 in atherosclerosis but not in the prevention of
fatty streak formation by 17beta-estradiol in apolipoprotein E-deﬁcient mice.
Atherosclerosis 2001;156:315–20.
[186] Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacer-
bates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999;19:
2364–7.
[187] Ridker PM,  Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of
interleukin-6 and the risk of future myocardial infarction among apparently
healthy men. Circulation 2000;101:1767–72.
[188] Enomoto T, Ohashi K, Shibata R, Higuchi A, Maruyama S, Izumiya Y, Walsh
K,  Murohara T, Ouchi N. Adipolin/C1qdc2/CTRP12 protein functions as
an  adipokine that improves glucose metabolism. J Biol Chem 2011;286:
34552–8.
[189] Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M,  Hara Y. Omentin, a
novel adipocytokine inhibits TNF-induced vascular inﬂammation in human
endothelial cells. Biochem Biophys Res Commun 2011;408:339–43.[190] Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, Kataoka Y,
Ohashi K, Daida H, Kihara S, Ogawa H, Murohara T, Ouchi N. Fat-derived factor
omentin stimulates endothelial cell function and ischemia-induced revascu-
larization via endothelial nitric oxide synthase-dependent mechanism. J Biol
Chem 2012;287:408–17.
